Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tavolimab (Primary)
- Indications Cervical cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 14 Aug 2020 Results published in the Clinical Cancer Research
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2017 Planned End Date changed from 1 May 2020 to 2 Mar 2020.